Details for New Drug Application (NDA): 062718
NDA 062718 describes OMNIPEN-N, which is a drug marketed by Wyeth Ayerst and is included in two NDAs. Additional details are available on the OMNIPEN-N profile page.
The generic ingredient in OMNIPEN-N is ampicillin sodium. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ampicillin sodium profile page.
The generic ingredient in OMNIPEN-N is ampicillin sodium. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ampicillin sodium profile page.
Summary for 062718
| Tradename: | OMNIPEN-N |
| Applicant: | Wyeth Ayerst |
| Ingredient: | ampicillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062718
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 125MG BASE/VIAL | ||||
| Approval Date: | Dec 16, 1986 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 250MG BASE/VIAL | ||||
| Approval Date: | Dec 16, 1986 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Dec 16, 1986 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
